An active national survey of the BNT162b2 mRNA COVID-19 vaccine safety in Israeli children
- 1Israel Center for Disease Control, Israel Ministry of Health, Ramat Gan, Israel
- 2School of Public Health, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- 3School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
Abstract
The urgent need for COVID-19 vaccines led to rapid mRNA vaccine development, making safety evaluation essential for current vaccination programs and future mRNA vaccines, particularly in children. To systematically evaluate adverse events (AEs) following two BNT162b2 doses in 5–11-year-old children, including those with comorbidities, a national telephone survey (January–March 2022) was conducted among parents of children who had received the second BNT162b2 dose 21–30 days prior. Children were randomly sampled from the national vaccination registry. For each dose, multivariable logistic regression identified associations between children’s characteristics and any AE. Overall, 2,229 children participated (response rate 76.0%); 9.6% had chronic diseases, and 9.2% had pre-existing allergic conditions. Any AE was reported in 58.5%, mainly local (55.7%) or systemic (20.2%); the most common were local pain (54.7%) and fatigue (14.6%), respectively. Most local and systemic AEs resolved within 3 days; medical care was sought for only 1.0% of local and 5.7% of systemic AEs, and no hospitalizations were reported. For both doses, any AE was significantly associated with younger age (first/second doses: aOR = 0.94, 95% CI: 0.90–0.98; aOR = 0.96, 95% CI: 0.92–0.99), female sex (aOR = 1.38, 95% CI: 1.15–1.64 for both), and pre-existing allergic conditions (first/second doses: aOR = 1.99, 95% CI: 1.45–2.74; aOR = 1.71, 95% CI: 1.24–2.35). AE onset, duration, and relative severity were similar regardless of pre-existing allergic status. Exacerbation of chronic and allergic conditions occurred in 4.8% and 2.2%, respectively. BNT162b2 demonstrated a favorable short-term safety profile among children, including those with comorbidities. This study may help inform development and implementation of new mRNA vaccine targets for children.
Related
- Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine
- Association between prior HBV vaccine responsiveness and booster-induced anti-SARS-CoV-2 spike antibody titers following the third BNT162b2 dose in Japanese healthcare workers: A prospective observational study
- Estimation of mRNA-1283 vs BNT162b2 COVID-19 Vaccine Effectiveness in Older US Veterans
- Association Between Consumption of Foods Classified by Chewiness Level and Overweight/Obesity Among Israeli Adolescents: Insights from a Cross-Sectional National Youth Survey
- National trends of unique-PCV20 / PCV21 serotypes, common PCV20-PCV21 and non-vaccine serotypes causing invasive pneumococcal disease in adults in Spain during the period 2009-2026
BibTeX
@article{zatlawi2026active,
title = {{An active national survey of the BNT162b2 mRNA COVID-19 vaccine safety in Israeli children}},
author = {Miri Zatlawi and Aharona Glatman-Freedman and Dvora Frankenthal and Ziv Karni-Efrati and Rita Dicthiar and Lital Keinan-Boker and Michal Bromberg},
journal = {Human Vaccines \& Immunotherapeutics},
year = {2026},
month = nov,
doi = {10.1080/21645515.2026.2749219},
url = {https://doi.org/10.1080/21645515.2026.2749219},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - An active national survey of the BNT162b2 mRNA COVID-19 vaccine safety in Israeli children
AU - Miri Zatlawi
AU - Aharona Glatman-Freedman
AU - Dvora Frankenthal
AU - Ziv Karni-Efrati
AU - Rita Dicthiar
AU - Lital Keinan-Boker
AU - Michal Bromberg
PY - 2026
DA - 2026/11/09
JO - Human Vaccines & Immunotherapeutics
DO - 10.1080/21645515.2026.2749219
UR - https://doi.org/10.1080/21645515.2026.2749219
AB - The urgent need for COVID-19 vaccines led to rapid mRNA vaccine development, making safety evaluation essential for current vaccination programs and future mRNA vaccines, particularly in children. To systematically evaluate adverse events (AEs) following two BNT162b2 doses in 5–11-year-old children, including those with comorbidities, a national telephone survey (January–March 2022) was conducted among parents of children who had received the second BNT162b2 dose 21–30 days prior. Children were randomly sampled from the national vaccination registry. For each dose, multivariable logistic regression identified associations between children’s characteristics and any AE. Overall, 2,229 children participated (response rate 76.0%); 9.6% had chronic diseases, and 9.2% had pre-existing allergic conditions. Any AE was reported in 58.5%, mainly local (55.7%) or systemic (20.2%); the most common were local pain (54.7%) and fatigue (14.6%), respectively. Most local and systemic AEs resolved within 3 days; medical care was sought for only 1.0% of local and 5.7% of systemic AEs, and no hospitalizations were reported. For both doses, any AE was significantly associated with younger age (first/second doses: aOR = 0.94, 95% CI: 0.90–0.98; aOR = 0.96, 95% CI: 0.92–0.99), female sex (aOR = 1.38, 95% CI: 1.15–1.64 for both), and pre-existing allergic conditions (first/second doses: aOR = 1.99, 95% CI: 1.45–2.74; aOR = 1.71, 95% CI: 1.24–2.35). AE onset, duration, and relative severity were similar regardless of pre-existing allergic status. Exacerbation of chronic and allergic conditions occurred in 4.8% and 2.2%, respectively. BNT162b2 demonstrated a favorable short-term safety profile among children, including those with comorbidities. This study may help inform development and implementation of new mRNA vaccine targets for children.
SN - 2164-5515
SN - 2164-554X
ER -